TAK (Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock))
Insider Trading Activity
Every open-market purchase and sale reported by TAK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Andrew Stewart Plump | President, R&D | Sell | — | — |
| 2026-08-21 | Andrew Stewart Plump | President, R&D | Sell | — | — |
| 2026-08-19 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell | — | — |
| 2026-08-12 | Gabriele Ricci | Chief Data & Tech. Officer | Sell | — | — |
| 2026-08-12 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell | — | — |
| 2026-08-12 | Julie So-Young Kim | President and CEO | Sell | — | — |
| 2026-08-12 | Teresa Marie Bitetti | President, OBU | Sell | — | — |
| 2026-08-12 | Giles Richard Platford | President, IBU | Sell | — | — |
| 2026-08-12 | Andrew Stewart Plump | President, R&D | Sell | — | — |
| 2026-08-12 | Lauren Rusckowski Duprey | Chief Transformation Officer | Sell | — | — |
| 2026-08-12 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | Sell | — | — |
| 2026-08-12 | Elaine Mary Shannon | Pres., Global Supply & Quality | Sell | — | — |
| 2026-08-12 | Ramy Riad Ahmed Ibrahim | President, PDT BU | Sell | — | — |
| 2026-08-12 | Awny Samaan Botros Farajallah | Chief Medical Officer | Sell | — | — |
| 2026-08-12 | Natalie Anne Marie Furney | Global General Counsel | Sell | — | — |
| 2026-08-12 | Elaine Mary Shannon | Pres., Global Supply & Quality | Sell | — | — |
| 2026-08-12 | Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev | Sell | — | — |
| 2026-08-12 | Rhonda Janice Pacheco | President, U.S. Business Unit | Sell | — | — |
| 2026-07-06 | Ramy Riad Ahmed Ibrahim | President, PDT BU | A | — | — |
| 2026-07-06 | Jennifer Marie Smoter | Chief Comm. & Gov. Officer | A | — | — |
| 2026-07-06 | Rhonda Janice Pacheco | President, U.S. Business Unit | A | — | — |
| 2026-07-06 | Nicola Deidre Petal Greenway | Chief Human Resources Officer | A | — | — |
| 2026-07-06 | Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev. | A | — | — |
| 2026-07-06 | Teresa Marie Bitetti | President, OBU | A | — | — |
| 2026-07-06 | Elaine Mary Shannon | Pres., Global Supply & Quality | A | — | — |
| 2026-07-06 | BRUCE D BROUSSARD | Director | A | — | — |
| 2026-07-06 | Koichiro Kimura | Director | A | — | — |
| 2026-07-06 | Giles Richard Platford | President, IBU | A | — | — |
| 2026-07-06 | Miki Tsusaka | Director | A | — | — |
| 2026-07-06 | Lauren Rusckowski Duprey | Chief Transformation Officer | A | — | — |
| 2026-07-06 | Gabriele Ricci | Chief Data & Tech. Officer | A | — | — |
| 2026-07-06 | Paulus Stoffels | Director | A | — | — |
| 2026-07-06 | Awny Samaan Botros Farajallah | Chief Medical Officer | A | — | — |
| 2026-07-06 | Natalie Anne Marie Furney | Global General Counsel | A | — | — |
| 2026-07-06 | Milano Furuta | Chief Financial Officer | A | — | — |
| 2026-07-06 | Julie So-Young Kim | President and CEO | A | — | — |
| 2026-07-06 | Asuka Miyabashira | President, Japan Pharma B.U. | A | — | — |
| 2026-07-06 | STEVEN GILLIS | Director | A | — | — |
| 2026-07-06 | Kimberly A. Reed | Director | A | — | — |
| 2026-07-06 | Masami Iijima | Director | A | — | — |
| 2026-07-06 | Andrew Stewart Plump | President, R&D | A | — | — |
| 2026-07-06 | JOHN MARAGANORE | Director | A | — | — |
| 2026-04-28 | Julie So-Young Kim | CEO - Elect | A | — | — |
| 2026-04-28 | Teresa Marie Bitetti | President, OBU | A | — | — |
| 2026-04-28 | Agosti Marcello Pignagnoli | Head, Strat. & Port. Dev. | A | — | — |
| 2026-04-28 | Lauren Rusckowski Duprey | Chief Transformation Officer | A | — | — |
| 2026-04-28 | Andrew Stewart Plump | President, R&D | A | — | — |
| 2026-04-28 | Milano Furuta | Chief Financial Officer | A | — | — |
| 2026-04-28 | Giles Richard Platford | President, IBU | A | — | — |
| 2026-04-28 | Gabriele Ricci | Chief Data & Tech. Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | President and CEO | 1,014,200 | — |
| — | President, R&D | 912,034 | — |
| — | President and CEO | 391,489 | — |
| — | President, IBU | 315,838 | — |
| — | President, OBU | 252,010 | — |
| — | Chief Transformation Officer | 226,057 | — |
| — | Global General Counsel | 204,298 | — |
| — | President, U.S. Business Unit | 182,507 | — |
| — | Head, Strat. & Port. Dev | 176,977 | — |
| — | Chief Data & Tech. Officer | 171,654 | — |
| — | Chief Medical Officer | 116,177 | — |
| — | President, PDT BU | 102,588 | — |
| — | Chief Financial Officer | 70,200 | — |
| — | Pres., Global Supply & Quality | 63,333 | — |
| — | Chief Human Resources Officer | 40,049 | — |
| — | Chief Comm. & Gov. Officer | 18,808 | — |
| — | Director | 15,175 | — |
| — | Director | 14,601 | — |
| — | Director | 13,800 | — |
| — | Director | 10,400 | — |
| — | Director | 8,200 | — |
| — | Director | 4,595 | — |
| — | President, Japan Pharma B.U. | 4,500 | — |
| — | Director | 3,800 | — |
| — | Director | 1,800 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TAK quote page; the site-wide leaderboard is on the insider transactions hub.